Table 4. Plasma levels of GDF-15 (pg/mL), vWF (%) and hsCRP (mg/L) in testicular cancer patients (n = 41) before, during and after completion of bleomycin- and cisplatin-based chemotherapy.
| GDF-15 (pg/mL) | vWF (%) | hsCRP (mg/L) | ||||
|---|---|---|---|---|---|---|
| Median | Range | Median | Range | Median | Range | |
| Course1 | ||||||
| Day 1 (= baseline) | 383.1 | 186.8–1935.0 | 100 | 42–297 | 2.0 | 0.2–87.1 |
| Day 8 | 3473.7 * | 1344.5–9028.3 | 164* | 56–319 | 0.6* | 0.2–4.9 |
| Day 15 | 1587.2 * | 655.2–4014.9 | 145* | 57–394 | 4.2† | 1.1–101.0 |
| Course 2 | ||||||
| Day 1 | 1145.5 * | 593.6–3074.5 | 143* | 34–360 | 5.1 | 1.1–39.8 |
| Day 8 | 4898.0 * | 2183.0–10794.9 | 197* | 66–464 | 0.6* | 0.2–21.1 |
| Course 3 | ||||||
| Day 1 | 2067.7 * | 639.0–4918.0 | 194* | 66–440 | 3.7 | 0.3–39.9 |
| Day 8 | 5542.8 * | 702.3–18958.9 | 197* | 81–419 | 0.6 | 0.2–25.7 |
| One month after completion of chemotherapy | ||||||
| 1009.6 * | 409.7–4737.1 | 135* | 56–249 | 2.2 | 0.4–29.1 | |
| One year after start of chemotherapy | ||||||
| 395.2 * ‡ | 246.9–913.2 | 115* ‡ | 49–218 | 1.5§ | 0.2–14.3 | |
* P < 0.01 compared to baseline, Wilcoxon signed rank test
† P < 0.05 compared to baseline, Wilcoxon signed rank test
‡ P < 0.01 compared to one month after completion of chemotherapy, Wilcoxon signed rank test
§ P < 0.05 compared to one month after completion of chemotherapy, Wilcoxon signed rank test